Compounds 1, 2 and 4 increased doxorubicin accumulation and efficacy in cancer cells that co-express CAXII and Pgp, with the same efficacy of tariquidar, one of the strongest third-generation Pgp inhibitors known [22], used in phase I and phase II clinical trials (https://clinicaltrials.gov). Here, CA12 is linked to cancer.